Germany's Evotec has taken legal steps against Israel's Andromeda Biotech in an effort to recoup its losses following Andromeda's falsification of trial results for diabetes drug DiaPep277. Evotec's stock took a dive when the deception came to light earlier in September and has yet to recover.
Andromeda was developing DiaPep277 as a treatment for type 1 diabetes, and data from the program was what attracted Hyperion...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?